VivoSeq
Immunology

Autoimmune Diseases

2

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Autoimmune Diseases is an early-stage landscape with 2 programs across 3 companies. The most active players are BeiGene, Eli Lilly, Fresenius Medical Care Deutschland GmbH.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1F

Fresenius Medical Care Deutschland GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

4SCAR T Cells

Shenzhen Geno-Immune Medical Institute

Phase 11

BGB-45035

BeiGene

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Cell therapy150%

Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting4 · 80%
Completed1 · 20%

Clinical Trials

Trial Activity

Study of STIM1 Membrane Expression During Autoimmune Diseases
Recruiting·UUniversity Hospital, Brest·N/A·NCT04978948·670 enrolled
Clinical Performance of the New Plasma Filter PX2 in Combination With the multiFiltrate and multiFiltratePRO in TPE Treatments
Recruiting·FFresenius Medical Care Deutschland GmbH·Preclinical·NCT06382675·46 enrolled
CAR-T Cells Targeting B Cell Related Autoimmune Diseases
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT05459870·30 enrolled
Management of Autoimmune Conditions With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT06435897·30 enrolled
Phase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases
Completed·BeiGene logoBeiGene·Phase 1·NCT06342713·203 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)